Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?

References

• Romaguera JE, Fayad L, Rodriguez MA, et al High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 2005;105:2677–2684.
   PubMed Web of Science ®Google Scholar
• Damon LE, Johnson JL, Niedzwiecki D, et al Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:6101–6108.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
   PubMed Web of Science ®Google Scholar
• van't Veer MB, de Jong D, MacKenzie M, et al High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524–530.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Hosein PJ, Morgensztern D, et al High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2010;51:XXX–XXX.
   Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Geisler C, Kolstad A, Laurell A, Raty R; Nordic Lymphoma Group. Mantle cell lymphoma – does primary intensive immunochemotherapy improve overall survival for younger patients? Leuk Lymphoma 2009;50:1249–1256.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Jung SH, Lai R, et al Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008;49:2081–2090.
   PubMed Web of Science ®Google Scholar
• Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the international prognostic index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002;69:11–20.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, et al Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL network. Br J Haematol 2005;131:29–38.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al WHO classification of haematopoietic and lymphoid tumours. 4th ed. Lyon: IARC; 2008.
   Google Scholar
• Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008;142:149–165.
   PubMed Web of Science ®Google Scholar
• Dave SS, Fu K, Wright GW, et al Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431–2442.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, et al Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144–4152.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, et al Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587–593.
   PubMed Web of Science ®Google Scholar
• Kahl B, Chang J, Eickhoff J, et al VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network. Blood 2008;112(Suppl. 1): 105 (Abstract 265).
   PubMed Web of Science ®Google Scholar
• European Mantle Cell Lymphoma Network [accessed 6 Jan 2010]. Available from: http://www.european-mcl.net/en/index.php.
   Google Scholar
• Kaufmann H, Raderer M, Wohrer S, et al Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269–2271.
   PubMed Web of Science ®Google Scholar
• Epner EM, Unger J, Miller T, et al A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007;110(Suppl. 1): (Abstract 387).
   PubMed Web of Science ®Google Scholar